Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2022-02-03 00:00:00 ET · period of report 2022-02-01 · accession 0000899243-22-004665 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-02-03 | 2022-02-01+ | VRDN | Violin Jonathan | CEO, Dir | S - Sale | $19.09 | -30.0K | 600.9K | -5% | -$572.8K |
| D | 2022-02-03 | 2022-02-02 | VRDN | Violin Jonathan | CEO, Dir | A - Grant | $0.00 | +280.0K | 280.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | S | D | 16,751 | $19.55 | 614,154 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.90 to $20.23. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2022-02-02 | S | D | 12,340 | $18.47 | 601,814 | D | — | — | (F2) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.32 to $19.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2022-02-03 | S | D | 909 | $19.16 | 600,905 | D | — | — | (F3) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.04 to $19.66. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-02-02 | A | A | 280,000 | $0.00 | 280,000 | D | $18.51 · — to 2032-02-02 | 280,000 Common Stock | (F4) The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. |